These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672 [TBL] [Abstract][Full Text] [Related]
65. [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma]. Wang LX; Lu H; Shen WY; Qian SX; Qiu HX; Wu HX; Zhang JF; Wu YJ; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):943-5. PubMed ID: 18718096 [TBL] [Abstract][Full Text] [Related]
67. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma. Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450 [TBL] [Abstract][Full Text] [Related]
68. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. Ludwig H; Weisel K; Petrucci MT; Leleu X; Cafro AM; Garderet L; Leitgeb C; Foa R; Greil R; Yakoub-Agha I; Zboralski D; Vauléon S; Dümmler T; Beyer D; Kruschinski A; Riecke K; Baumann M; Engelhardt M Leukemia; 2017 Apr; 31(4):997-1000. PubMed ID: 28074071 [No Abstract] [Full Text] [Related]
69. XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach. Chanukuppa V; Paul D; Taunk K; Chatterjee T; Sharma S; Kumar S; Santra MK; Rapole S J Proteomics; 2019 Oct; 209():103504. PubMed ID: 31465861 [TBL] [Abstract][Full Text] [Related]
70. Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients. Zhang L; Mager DE J Pharm Sci; 2019 Jan; 108(1):732-740. PubMed ID: 30472266 [TBL] [Abstract][Full Text] [Related]
71. The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. Martinez-Sanchez J; Palomo M; Torramade-Moix S; Moreno-Castaño AB; Rovira M; Gutiérrez-García G; Fernández-Avilés F; Escolar G; Penack O; Rosiñol L; Carreras E; Diaz-Ricart M Bone Marrow Transplant; 2020 Dec; 55(12):2270-2278. PubMed ID: 32404979 [TBL] [Abstract][Full Text] [Related]
72. Evaluation of serum glucose-regulated protein 78 (GRP78) as a biomarker of treatment response to bortezomib-based induction regimen in multiple myeloma: A cross-sectional pilot study. Ramachandran SS; Gupta P; Kumar L; Gupta R; Goel L; Kumar VL; Gupta YK Neoplasma; 2022 Dec; 69(6):1451-1458. PubMed ID: 36591800 [TBL] [Abstract][Full Text] [Related]
73. [Efficacy and prognosis of PAD combination therapy for fifty-six previously untreated patients with multiple myeloma]. Yan S; Fu CC; Ma L; Zhou J; Jin S; Yan LZ; Zhu XM; Wang PF; Xu Y; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):520-2. PubMed ID: 27431080 [No Abstract] [Full Text] [Related]
74. [Successful treatment of one case with relapsed refractory multiple myeloma by chidamide in combination with bortezomib and dexamethasone]. Wang DY; Cui YS; Liu YZ; Liu LN; Song YP; Fang BJ Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):463. PubMed ID: 27431068 [No Abstract] [Full Text] [Related]
75. CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. Bögelein A; Stolzenburg A; Eiring P; Lückerath K; Munawar U; Werner R; Schirbel A; Samnick S; Kortüm KM; Sauer M; Lapa C; Buck AK Leuk Lymphoma; 2022 Oct; 63(10):2393-2402. PubMed ID: 35802888 [TBL] [Abstract][Full Text] [Related]
76. Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. Parrondo RD; Roy V; Sher T; Alegria V; Chanan-Khan AA; Ailawadhi S Case Rep Hematol; 2020; 2020():4360926. PubMed ID: 32148978 [TBL] [Abstract][Full Text] [Related]
77. Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres. McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A Bone Marrow Transplant; 2021 Mar; 56(3):738-740. PubMed ID: 33077903 [No Abstract] [Full Text] [Related]
78. Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Giliberto M; Thimiri Govinda Raj DB; Cremaschi A; Skånland SS; Gade A; Tjønnfjord GE; Schjesvold F; Munthe LA; Taskén K Mol Oncol; 2022 Mar; 16(6):1241-1258. PubMed ID: 35148457 [TBL] [Abstract][Full Text] [Related]
79. A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis. Okur E; Yerlikaya A Cell Biol Toxicol; 2019 Feb; 35(1):33-47. PubMed ID: 29948483 [TBL] [Abstract][Full Text] [Related]
80. Significance of paraprotein gap and β2 microglobulins in predialysis Population with multiple myeloma. Ali H; Kishore B; Baharani J Saudi J Kidney Dis Transpl; 2019; 30(4):825-831. PubMed ID: 31464239 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]